Combination antiplatelet agents in ischemic cerebrovascular disease

Mount Sinai Journal of Medicine

Volumn 72, Issue 1, 2005, Pages 16-22

  Moussouttas, Michael ^a,b   Papamitsakis, Nikolaos ^a  

^a SETON HALL UNIVERSITY   (United States)

^b NEW JERSEY NEUROSCIENCE INSTITUTE   (United States)

Author keywords

Antiplatelet; Aspirin; Cerebral; Cerebrovascular; Clopidogrel; Combination therapy; Dipyridamole; Infarction; Ischemia; Vascular

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ORAL ANTIDIABETIC AGENT; TICLOPIDINE; WARFARIN;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; BLEEDING; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEMENTIA; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; HEART PROTECTION; HUMAN; HYPOTENSION; OUTCOMES RESEARCH; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SUSTAINED DRUG RELEASE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TICLOPIDINE;

EID: 13944251442     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Warlow C. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. Stroke 2002; 33(8):2137-2138.
2. Diener HC. Aspirin therapy should be first-line treatment in the secondary prevention of stroke - against. Stroke 2002; 33(8):2138-2139.
3. Herbert JM, Bernat A, Samama M, Maffrand JP. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb Haemost 1996; 76(1):94-98.
4. Herbert JM, Dol F, Bernat A, et al. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998; 80(3):512-518.
5. Muller TH. Inhibition of thrombus formation by low-dose acetylsalicylic acid, dipyridamole, and their combination in a model of platelet-vessel wall interaction. Neurology. 2001;57(5 Suppl 2): S8-S11.
6. Pettigrew LC. Antithrombotic, drugs for secondary stroke prophylaxis. Pharmacotherapy 2001; 21(4):452-463.
7. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989(8649); 1:1215-1220.
8. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321(8):501-507.
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348(9038):1329-1339.
10. Diener H, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143(1-2):1-13.
11. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339(23):1665-1671.
12. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7):494-502. Errata in: N Engl J Med 2001; 345(23):1716 and N Engl J Med 2001; 345(20):1506.
13. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288(19):2411-2420. Erratum in JAMA 2003; 289(8):987.
14. Wilterdink JL, Easton JD. Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 1999; 56(9):1087-1092.
15. Albers GW. Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients? Neurology 2000; 54(5):1022-1028.
16. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002; 33(4):901-906.
17. Cohen SN. Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 2000; 57(7):1086-1087.
18. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002; 288(11):1388-1395.
19. Donnan GA, Davis SM. Aspirin therapy should be first line: probably, but watch this space. Stroke 2002; 33(8):2139-2140.
20. Dyken ML. Secondary prevention for stroke after CAPRIE and ESPS-2. Opinion 2. Cerebrovasc Dis 1998; 8(2):75-77.
21. The American-Canadian Co-Operative Study group. Persantine Aspirin Trial in cerebral ischemia. Part II: endpoint results. Stroke 1985; 16(3):406-415.
22. Bousser MG, Eschwege E, Haguenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14(1):5-14.
23. Guiraud-Chaumeil B, Rascol A, David J, et al. Prévention des recidives des accidents vasculaires cérébraux ischémiques par les antiagregants plaquettaires [French]. Rev Neurol (Paris) 1982; 138(5):367-385.
24. Enserink M. Fraud and ethics charges hit stroke drug trial. Science 1996; 274(5295):2004-2005.
25. Davis SM, Donnan GA. Secondary prevention for stroke after CAPRIE and ESPS-2. Opinion 1. Cerebrovasc Dis 1998; 8(2):73-75.
26. Theis JG, Deichsel G, Marshall S. Rapid development of tolerance to dipyridamole-associated headaches. Br J Clin Pharmacol 1999; 48(5):750-755.
27. Dresse A, Chevolet C, Delapierre D, et al. Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982; 23(3):229-234.
28. Sarasin FP, Gaspoz JM, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med 2000; 160(18):2773-2778.
29. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325(18):1261-1266.
30. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection against cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996; 60(2):197-199.
31. Albers GW, Amarenco P. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascular patients? Stroke 2001; 32(12):2948-2949.
32. Alberts MJ, Easton JD. Clopidogrel plus aspirin for stroke prevention. Stroke 2002; 33(11):2546-2547.
33. Albers GW, Tijssen JG. Antiplatelet therapy: new foundations for optimal treatment decisions. Neurology 1999; 53(7 Suppl 4):S25-S31.
34. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136(2):161-172.
35. ACC/AHA Practice Guidelines. Task Force on Practice Guidelines. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-st segment elevation myocardial infarction. 2002. www.acc.org/clinical/guidelines/unstable.pdf (accessed 12/20/03).
36. Keltz TN, Innerfield M, Gitler B, Cooper JA. Dipyridamole-induced myocardial ischemia. JAMA 1987; 257(11):1515-1516.
37. Boehringer-Ingelheim Pharmaceuticals Inc. Aggrenox package insert. Ridgefield, CT. 2000.
38. Siegel AM, Sandor P, Kollias SS, Baumgartner RW. Transient ischemic attacks after dipyridamole-aspirin therapy. J Neurol 2000; 247(10):807-808.
39. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
40. De Schryver EL. ESPRIT Study Group. Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. Stroke 2003; 34(10):2339-2342.
41. Ishikawa K, Kanamasa K, Hama J, et al. Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. Jpn Circ J 1997; 61(1):38-45.
42. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342(24):1773-1777.
43. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107(1):32-37.
44. Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur Heart J 2003; 24(19):1744-1749.
45. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108(8):921-924.
46. Smith-Kline Beecham. Ecotrin package insert. Pittsburgh, PA. 2000.
47. Alberts MG, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35(1):175-178.
48. Gorelick PB, Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. Stroke 2002; 33(3):862-875.
49. Washington University in St. Louis. Internet Stroke Center. Stroke Trials Directory, 2004. www.strokecenter.org/trials/(accessed on 5/21/04).